Home
|
Login
|
Job Seeker Register
|
Employer Register
You're not logged in!
Job Search
Search Jobs by Type
Search USA Map
Search World Map
Job Fair Schedule
Job Seekers Info
Testimonials
Interview Insight
Pharm Rep Books
Military Transitioning
Stock Quote Update
Smile
Employer Info
PharmaDiversity Partners
Post Jobs
Advertise with Us
Testimonials
Stock Quote Update
About Us
Contact Us
FAQ
Translate:
Select Language
English Version to Apply
Spanish
Chinese
French
Nycomed Jobs
Click links to read Current News for this Featured Employer
Nycomed's U.S. Patent for Protonix(R) (pantoprazole) Valid
|
Steve Andrzejewski Joins Nycomed US Inc.
|
DURECT Reports Data From European Phase IIb Hysterectomy Study of POSIDUR(TM) (SABER(TM)-Bupivacaine)
|
New Interim Results From European Patient Survey Add Weight to Expert Call for Greater Clinical Consensus on Breakthrough Cancer Pain
|
DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
|
Bioamber Commissions World's First Renewable Succinic Acid Plant
|
DURECT Initiates U.S. Pivotal Phase III POSIDUR(TM) Clinical Trial
|
DURECT Reports Positive Phase IIb Data from POSIDUR(TM) Clinical Program
|
Instanyl(R) (intranasal fentanyl spray) Sets New Standard in Management of Breakthrough Cancer Pain
|
Nycomed and Forest Laboratories to Collaborate on US Commercialisation of Daxas(R) in COPD
|
Nycomed Announces FDA Filing for Daxas(R) in COPD - New drug application filed for United States- Treatment aimed at patients with symptomatic Chronic Obstructive Pulmonary Disease (COPD)- Data show reductions in moderate and severe exacerbations requiring medical intervention- Partnering process underway for US commercialisation
|
Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203
|
Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
|
Frost & Sullivan Commends Nycomed for Excellence in Product Differentiation Innovation
|
Micromet Key Events for 2009
|
Nycomed?s Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
|
FDA Approves Fougera?s Clotrimazole Cream USP 1%
|
Pharmaderm Annnounces the Arrival of KEROL(TM) ZX and KEROL(TM) Emulsion to Market
|
Items 1-6/6 displayed.
[1-6]
Save
Date
Job Title
City Country
State
Company Name
Pay
Aug 20
Compounder
Hicksville
New York
Nycomed
Not specified
Jul 30
Legal Assistant
Melville
New York
Nycomed
Not specified
Jul 27
Director Assoc Project Mgmt
Melville
New York
Nycomed
Not specified
Jul 27
Sr Manager R&D Process Engineering
Melville
New York
Nycomed
Not specified
Jul 26
Warehouse Worker
Warehouse Worker
Hicksville
New York
Nycomed
Not specified
Jul 26
Project Engineer
Project Engineer
Hicksville
New York
Nycomed
Not specified